Search Results

You are looking at 241 - 250 of 578 items for :

  • Refine by Access: All x
Clear All
Full access

Neoadjuvant Immunotherapy–Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series

Rahel Demisse, Neha Damle, Edward Kim, Jun Gong, Marwan Fakih, Cathy Eng, Leslie Oesterich, Madison McKenny, Jingran Ji, James Liu, Ryan Louie, Kit Tam, Sepideh Gholami, Wissam Halabi, Arta Monjazeb, Farshid Dayyani, and May Cho

, compatible with tumor regression grade 1. The patient continued to have partial response on subsequent imaging, and tolerated, in total, 11 cycles of pembrolizumab. However, he developed grade 2 fatigue attributed to immunotherapy, which led to therapy

Full access

NCCN Policy Summit: Defining, Measuring, and Applying Quality in an Evolving Health Policy Landscape and the Implications for Cancer Care

Lindsey A.M. Bandini, Leigh Gallo, Terrell Johnson, Kara Martin, Alyssa A. Schatz, Kerin Adelson, Bryan A. Loy, Ronald S. Walters, Tracy Wong, and Robert W. Carlson

care issues, which the panelists offered as an opportunity for enhancement of the OCM. 10 With an increase in data collection, panelists also warned of survey fatigue, or physician and patient burnout resulting from extensive surveying. Relying on sick

Full access

First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition

Victor T.G. Lin, Lisle M. Nabell, Sharon A. Spencer, William R. Carroll, Shuko Harada, and Eddy S. Yang

BRAF. CDK inhibitors were also discussed, but not pursued. He remained on nivolumab for 3 months before discontinuation for severe fatigue unrelated to iatrogenic hypothyroidism or adrenal insufficiency. The patient was subsequently started on

Full access

Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma

Talia Golan and Pascal Hammel

common AEs were fatigue, nausea, and diarrhea. Anemia and fatigue were the most frequent grade ≥3 AEs. Other PARPi are being evaluated in patients with PDAC ( Table 1 ). In a randomized phase II study comparing modified FOLFIRI + veliparib versus

Full access

Loneliness and Mortality Risk Among Cancer Survivors in the United States: A Retrospective, Longitudinal Study

Jingxuan Zhao, Jennifer B. Reese, Xuesong Han, and K. Robin Yabroff

, lonelier cancer survivors might not receive the practical and emotional support they need for their symptoms, which could then impose greater health burdens, with earlier studies finding that loneliness was associated with symptoms such as fatigue, pain

Full access

NCCN News

Sleep Disorders, Fatigue, and Cognitive Function in Cancer Survivors—speakers again noted a lack of data. The panelists explained that there is good evidence showing that physical activity can help with cancer-related fatigue. But when it comes to other

Full access

Palliative Care

Michael H. Levy, Michael D. Adolph, Anthony Back, Susan Block, Shirley N. Codada, Shalini Dalal, Teresa L. Deshields, Elisabeth Dexter, Sydney M. Dy, Sara J. Knight, Sumathi Misra, Christine S. Ritchie, Todd M. Sauer, Thomas Smith, David Spiegel, Linda Sutton, Robert M. Taylor, Jennifer Temel, Jay Thomas, Roma Tickoo, Susan G. Urba, Jamie H. Von Roenn, Joseph L. Weems, Sharon M. Weinstein, Deborah A. Freedman-Cass, and Mary Anne Bergman

, malignant bowel obstruction, fatigue, weakness, asthenia, insomnia, daytime sedation, and delirium. Psychosocial Distress: Assessment of psychosocial distress should focus on illness-related distress and psychosocial, spiritual, or existential issues

Full access

Kidney Cancer

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, David Josephson, Timothy M. Kuzel, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Philippe E. Spiess, Jue Wang, and Richard B. Wilder

fatigue more common with IFN-α (12% vs. 7%). Updated results show an overall survival advantage of sunitinib over IFN-α in the first-line setting (26.4 vs. 21.81 months). 44 Recent data from an expanded access trial that was performed before the drug

Full access

Survivorship, Version 1.2021

Featured Updates to the NCCN Guidelines

Amye Tevaarwerk, Crystal S. Denlinger, Tara Sanft, Shannon M. Ansbaugh, Saro Armenian, K. Scott Baker, Gregory Broderick, Andrew Day, Wendy Demark-Wahnefried, Kristin Dickinson, Debra L. Friedman, Patricia Ganz, Mindy Goldman, Norah Lynn Henry, Christine Hill-Kayser, Melissa Hudson, Nazanin Khakpour, Divya Koura, Allison L. McDonough, Michelle Melisko, Kathi Mooney, Halle C.F. Moore, Natalie Moryl, Javid J. Moslehi, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Chirayu Patel, Lindsay Peterson, William Pirl, M. Alma Rodriguez, Kathryn J. Ruddy, Lidia Schapira, Lillie Shockney, Sophia Smith, Karen L. Syrjala, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass

survivors will not have returned to work at 2 years postdiagnosis. 15 – 17 Furthermore, those survivors who do return to work often encounter difficulties, such as physical or cognitive limitations, fatigue, depression, anxiety, and discrimination. 5 , 18

Full access

Radiation Therapy in Operable and Locally Advanced Pancreatic Cancer

Andrew H. Ko and Christopher H. Crane

toxicity (grade 3–4, 38% vs. 14%; P = .03) and fatigue (32% vs. 6%). 27 Thus, the addition of chemoradiation before standard chemotherapy resulted in a modest prolongation of median survival at the cost of a modest increase in toxicity that remained